TranscriptomeSciInc
@TranscriptomeSI
Followers
120
Following
138
Media
87
Statuses
208
Genomics company changing patient care through molecular diagnostics and the Molecular Microscope® (MMDx®) service.
Edmonton, Alberta
Joined April 2016
We're proud to share this concise overview of our work showcased at @ATCMeeting. The team has been driven over decades to provide improved diagnostic methods that will ultimately change patient care, & we're excited to share this glimpse into our work.
0
0
0
RT @TransplantJrnl: The Trifecta-Heart paper reports that dd-cfDNA plasma levels correlate significantly with molecular rejection with inju….
0
1
0
📢 New Publication Alert! 📢. Many kidney transplants labeled “no rejection” show hidden TCMR & ABMR. This subthreshold activity is linked to future rejection & graft loss. 🔬. Read more: #MMDx #MolecularMicroscope #KidneyTransplant #Rejection #TCMR #ABMR
0
3
3
📢HOT OFF THE PRESS!📢 Our latest publication, a definitive review of MMDx-Kidney, is available as an Open Access article. Check it out here! 👇👇👇#MolecularMicroscope #MMDx #kidneytransplantation #kidneybiopsy
0
0
0
Join us at the @ATCMeeting for Dr. Phil Halloran's Hot Topic Debate session! #ATC2024 #ATC24 #ATC2024Philly #MMDx
0
0
2
0
0
0
Join us at the @ATCMeeting for our Poster Presentation on the Trifecta-Kidney Study! #ATC2024 #ATC24 #ATC2024Philly #MMDx
0
0
3
Join us at the @ATCMeeting for our Poster Presentation on donor age in kidneys! #ATC2024 #ATC24 #ATC2024Philly #MMDx
0
0
1
Join us tomorrow at the @ATCMeeting for our Poster Presentation on the Trifecta-Kidney substudy! #ATC2024 #ATC24 #ATC2024Philly #MMDx
0
0
2
Join us at @ATCMeeting tomorrow for our Rapid Fire Oral on MMDx-Liver! #ATC2024 #ATC24 #ATC2024Philly #MMDx
0
0
2
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection . @ERAkidney |….
0
19
0
(1) Halloran, P. F., et al. (1990). "The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection." Transplantation 49(1): 85-91.
0
0
1
It also suggests that dd-cfDNA could be used to help manage these patients during treatment. We are committed to seeing how this agent can benefit kidney transplants with ABMR in a controlled phase 3 trial, hopefully led by our collaborators in Vienna and Berlin.
1
0
0
This is historic: since we first described ABMR as a microcirculation disease 34 years ago (1), this is the first controlled trial to show an agent that can suppress microcirculation inflammation.
1
0
0
The FELZ treatment suppressed ABMR molecular and histologic ABMR activity, particularly the NK cell genes, and suppressed dd-cfDNA.
1
0
0
We analyzed the molecular effects of Felzartamab (FELZ) anti-CD38 antibody on antibody-mediated rejection in kidney transplant recipients, in addition to changes in histology and circulating donor-derived cell-free DNA (dd-cfDNA).
1
0
0
We studied the problem of antibody-mediated rejection (ABMR), a microcirculation disease mediated by NK cells that damages the kidney microcirculation in thousands of kidney and heart transplant recipients.
1
0
0
We are excited to report the publication of our recent collaborative study with Vienna and Berlin, published in @nejm. @MayerKatherinaa @MatthiasDiebold @kodo_kd @FarsadE
1
0
2
This is historic: since we first described ABMR as a microcirculation disease 34 years ago (1), this is the first controlled trial to show an agent that can suppress microcirculation inflammation.
0
0
0
The FELZ treatment suppressed ABMR molecular and histologic ABMR activity, particularly the NK cell genes, and suppressed dd-cfDNA.
1
0
0
We analyzed the molecular effects of Felzartamab (FELZ) anti-CD38 antibody on antibody-mediated rejection in kidney transplant recipients, in addition to changes in histology and circulating donor-derived cell-free DNA (dd-cfDNA).
1
0
0